Research News

Supportive patient-practitioner relationships are crucial to the successful discontinuation of psychiatric medication.

Researchers argue that we need a paradigm shift away from the biomedical model of mental illness to one informed by political action and common sense.

Antidepressant trials with negative results are still more likely than not to either be misleadingly spun as positive or unpublished.

A study in JAMA Neurology finds that antidepressants do not reduce depression symptoms more than placebo in patients recovering from a stroke.

A review of research on antidepressant efficacy finds that an unfavorable risk-to-benefit ratio.

Researchers argue that common study methods for psychiatric drugs may inadvertently minimize withdrawal effects and inflate drug efficacy.

A new research article asserts that the overuse of psychiatric drugs may create neurobiological changes that hamper long-term mental health recovery.

Current long-term users of benzodiazepines and Z-drugs identify barriers and facilitators for discontinuation.

In JAMA Psychiatry, prominent psychiatrist Kenneth Kendler writes that psychiatric diagnoses are “working hypotheses, subject to change.”

A trial in veterans who had survived a previous suicide attempt was stopped early because the drug was found to be no better than a placebo.

Meta-analysis finds that the placebo run-in methodology reduces the placebo effect and finds antidepressants to be less useful.

Leading researchers point out that a new antidepressant study in NEJM failed to account for withdrawal symptoms, casting doubt on the results.

New guidance on how to taper and discontinue from psychiatric drugs from leading researchers Mark Horowitz and David Taylor.

“Patients expressed feeling unaccepted by society or uncomfortable in their own skin… A few indicated that they would rather be dead than have tardive dyskinesia.”

Long-term exposure to prolactin-increasing antipsychotics increases the odds of developing breast cancer.

Researchers developed a rating scale to better assess service users’ experiences tapering antidepressant and/or antipsychotic medication.

In JAMA psychiatry, researchers outline new theories connecting antipsychotic use in people with schizophrenia and increased dementia risk.

A new study finds that newborn babies experience antidepressant withdrawal after birth if their mothers take SSRIs when pregnant.

Research finds that social cognition and emotional processing abilities can be disrupted by psychiatric drugs.

Research suggests that slowly tapering off an antipsychotic reduces the risk of withdrawal psychosis compared to abrupt discontinuation.

A new study investigates how antidepressant withdrawal effects often get confounded with depression relapse in clinical trials.

A new article in Lancet Psychiatry debunks past studies claiming that those on low doses of antipsychotics are more likely to relapse.

A study of over 1.5 million people in Europe and the US links the development of less adaptive personalities with childhood lead exposure.

Researchers argue for a shift away from a focus on antipsychotic adherence toward understanding service users’ diverse patterns of use.

The CHR-P model focuses on “attenuated psychosis” to predict “transition” to schizophrenia and ignores other factors. But new research shows that the model is a poor predictor.